Medicinal products for human and investigational use / Derogations

The EESC:

• welcomes this package of measures;

• recognises that need to pay particular attention to the situation of smaller EU Member States, Cyprus, Ireland and Malta in particula;

• stresses in particular the central role of a functioning, fair and efficient internal market;

• welcomes the packaging requirements for UK products included in the package;

• draws attention to the need for a timely and sustainable solution, which should be developed within the framework of the European Pharmaceutical Strategy.